Methotrexate is a critical component of curative chemotherapy for pediatric acute lymphoblastic leukemia (ALL), but is associated with neurotoxicity. Information on long‐term outcomes following an acute neurotoxic event is limited. Therefore, this report compares neurocognitive performance more than 12 months post diagnosis (mean = 4 years) between ALL patients with ( n = 25) and without ( n = 146) a history of acute neurotoxicity. Compared to children with no documented on‐treatment neurotoxic event, children who experienced a neurotoxic event during treatment exhibited poorer performance on measures of fine motor function ( p = .02) and attention ( p = .02). Children with ALL who experience acute neurotoxicity may be candidates for early neuropsychological screening and intervention.
No takes yet. Share an insight, caveat, or question.
Harris et al. (2024) studied this question.